MarketCap
Facebook
X
Telegram
National Research Corporation Net Income | NRC
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income National Research Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.6 M | 24.8 M | 31 M | 31.8 M | 37.5 M | 37.3 M | 32.4 M | 30 M | 22.9 M | 20.5 M | 17.6 M | 18.2 M | 15.5 M | 15.1 M | 11.6 M | 11.6 M | 8.49 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.5 M | 8.49 M | 22.2 M |
Quarterly Net Income National Research Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.28 M | 3.22 M | 4.12 M | -106 K | 5.79 M | - | 5.69 M | 6.18 M | 6.36 M | - | 7.88 M | 7.27 M | 6.96 M | - | 8.3 M | 8.32 M | 8.54 M | - | 9.66 M | 8.94 M | 9.23 M | - | 9.58 M | 7.72 M | 11.8 M | - | 8.12 M | 7.39 M | 8.2 M | - | 6.99 M | 7.95 M | 7.31 M | - | 4.15 M | 5.75 M | 6.52 M | - | 4.73 M | 4.56 M | 5.51 M | - | 4.14 M | 4.06 M | 3.48 M | - | 4.55 M | 4.05 M | 5.45 M | - | 3.81 M | 3.43 M | 4.47 M | - | 3.58 M | 3.94 M | 3.85 M | - | 2.65 M | 2.33 M | 3.46 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.8 M | -3.28 M | 5.67 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-50 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Anixa Biosciences
ANIX
|
-10.9 M | $ 2.81 | 1.81 % | $ 91.2 K | USA |
|
Biodesix
BDSX
|
-35.3 M | $ 27.16 | 0.7 % | $ 205 M | USA |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Syneos Health
SYNH
|
266 M | - | - | $ 4.46 B | USA |
 |
Meridian Bioscience
VIVO
|
42.5 M | - | - | $ 1.49 B | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
-33.5 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Psychemedics Corporation
PMD
|
-1.86 M | - | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
-125 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
T2 Biosystems
TTOO
|
-50.1 M | - | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
Biomerica
BMRA
|
-3.78 M | $ 2.28 | 1.79 % | $ 6.65 M | USA |
 |
BioNano Genomics
BNGO
|
-26.4 M | $ 1.34 | 9.81 % | $ 7.3 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-55.3 M | $ 11.75 | 5.68 % | $ 124 M |  China |
 |
Bioventus
BVS
|
22.7 M | $ 13.21 | 1.77 % | $ 880 M | USA |
 |
CareDx, Inc
CDNA
|
-21.4 M | $ 52.06 | 3.58 % | $ 2.77 B | USA |
 |
Celcuity
CELC
|
-177 M | $ 83.18 | 0.07 % | $ 3.89 B | USA |
 |
Co-Diagnostics
CODX
|
-46.9 M | $ 1.14 | 1.83 % | $ 1.52 M | USA |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 269.68 | 0.06 % | $ 13.4 B | USA |
 |
Castle Biosciences
CSTL
|
-24.2 M | $ 32.99 | 2.04 % | $ 956 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
992 M | $ 237.41 | 1.06 % | $ 26.4 B | USA |
 |
Danaher Corporation
DHR
|
3.61 B | $ 202.7 | 1.27 % | $ 144 B | USA |
 |
DarioHealth Corp.
DRIO
|
-41.7 M | $ 7.1 | 2.45 % | $ 28.3 M | Israel |
 |
Brainsway Ltd.
BWAY
|
2.92 M | $ 13.66 | 0.14 % | $ 464 M | Israel |
 |
DexCom
DXCM
|
836 M | $ 84.28 | 1.5 % | $ 32.9 B | USA |
 |
Fulgent Genetics
FLGT
|
-60.5 M | $ 20.51 | 0.29 % | $ 631 M | USA |
 |
Guardant Health
GH
|
-416 M | $ 163.86 | 4.11 % | $ 20.5 B | USA |
 |
ICON Public Limited Company
ICLR
|
229 M | $ 169.16 | 0.97 % | $ 13.3 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.06 B | $ 507.97 | 0.65 % | $ 40.9 B | USA |
 |
Illumina
ILMN
|
850 M | $ 208.08 | 0.79 % | $ 32.3 B | USA |
 |
IQVIA Holdings
IQV
|
1.36 B | $ 264.32 | 0.98 % | $ 45.4 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
877 M | $ 311.9 | 0.1 % | $ 26 B | USA |
 |
Lantheus Holdings
LNTH
|
234 M | $ 100.28 | 0.02 % | $ 6.77 B | USA |
 |
Medpace Holdings
MEDP
|
451 M | $ 591.59 | 0.69 % | $ 17.1 B | USA |
 |
Mettler-Toledo International
MTD
|
869 M | $ 1 287.29 | 1.01 % | $ 26.5 B | Schweiz |
 |
Myriad Genetics
MYGN
|
-366 M | $ 3.66 | 7.02 % | $ 339 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-7.03 M | $ 5.68 | 0.98 % | $ 4.47 M | USA |
 |
NeoGenomics
NEO
|
-108 M | $ 17.9 | 3.35 % | $ 2.29 B | USA |
 |
Neogen Corporation
NEOG
|
-7.9 M | $ 11.86 | 0.64 % | $ 2.58 B | USA |
 |
Natera
NTRA
|
-208 M | $ 336.64 | 2.34 % | $ 46 B | USA |
 |
OPKO Health
OPK
|
-226 B | $ 1.56 | 0.38 % | $ 1.17 B | USA |
 |
Pacific Biosciences of California
PACB
|
-546 M | $ 1.36 | 4.23 % | $ 408 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
897 M | $ 25.17 | 2.28 % | $ 23.9 B |  Niderland |
 |
Personalis
PSNL
|
-81.3 M | $ 16.33 | 0.74 % | $ 1.46 B | USA |